Medarex Inc. has acquired preclinical research programs and other assets related to oncology from Corixa Corp. The $23.5 million deal was announced May 23.
Princeton, N.J.'s Medarex is a biopharmaceutical company that develops antibodies used to fight cancer and other life-threatening diseases.
Seattle's Corixa is a biotech c...
Princeton, N.J.'s Medarex is a biopharmaceutical company that develops antibodies used to fight cancer and other life-threatening diseases.
Seattle's Corixa is a biotech c...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In




